Activities Report March 2025 and Appendix 4C
| Stock | Osteopore Ltd (OSX.ASX) |
|---|---|
| Release Time | 29 Apr 2025, 8:22 a.m. |
| Price Sensitive | Yes |
Osteopore Reports Q1 2025 Results, Highlights Key Milestones
- Osteopore's revenue grows 26% QoQ despite headwinds
- Osteopore's implants added to Singapore's Ministry of Health subsidy list
- Osteopore draws down Tranche 1 of its redeemable convertible notes
Osteopore Limited (ASX:OSX), a revenue-generating manufacturer of regenerative implants, has released its quarterly results and Appendix 4C Quarterly Cash Flow Report for the three months ended 31 March 2025. Despite the impact of the South Korean medical crisis and the ongoing transformation of the business, Osteopore posted a solid recovery in Q1 CY25, with revenues up 26% QoQ to A$725,000 (S$613,000). The company's craniomaxillofacial and oculoplastic implants have now been listed on Singapore's Ministry of Health (MoH) Implant Subsidy List (ISL), enabling public healthcare patients to access Osteopore's cutting-edge solutions at a subsidised cost. Osteopore has also drawn down Tranche 1 of its Redeemable Convertible Note (RCN) with the Advance Opportunities Fund and Advance Opportunities Fund I, subscribing for 8 equal Sub-Tranches at a nominal value of A$2 million. Furthermore, Osteopore has ceased its $18.7m clinical-industrial dental project following a strategic review, enabling the reallocation of resources to strengthen its market position, enhance operational capacity, and drive sustainable growth. The company has also opened a clinical centre of excellence (CCoE) for medial wedge opening high tibial osteotomy (MOWHTO) in partnership with Total Orthopaedics Care & Surgery's Dr Hamid Razak, demonstrating its commitment to advancing orthopaedic care and improving patient outcomes.
Osteopore expects its Q1 CY25 revenue to increase by 26% to A$725,000 (S$613,000) compared to the previous quarter.
Osteopore is focused on strengthening its market position, enhancing operational capacity, and driving sustainable growth through the reallocation of resources following the early cessation of its dental project. The company is also committed to advancing orthopaedic care and improving patient outcomes through its new clinical centre of excellence.